Fig. 3

Genetics of tumors and correlation with treatment outcome. A Scheme showing the genotype of the 37 genes included in this study against the 27 PDX models analyzed. All types of mutations were combined and indicated as black squares, whereas the absence of a mutation is indicated as wildtype in green. Where low coverage did not allow an accurate assessment, this is indicated in grey. Response or lack of response to Erlotinib or Paclitaxel in the ZTX models is indicated with + or – respectively above the scheme. B Average relative expression of the 36 genes included in this study (EGFR is shown in Supplemental Fig. S2) as evaluated by RNA sequencing, for models responding (n = 14 models, blue bars) or resistant (n = 9 models, orange bars) to Erlotinib. *:p < 0.05, ***:p < 0.001. C Average relative expression of the 36 genes included in this study (EGFR is shown in Supplemental Fig. S2) as evaluated by RNA sequencing, for models responding (n = 18 models, blue bars) or resistant (n = 5 models, orange bars) to Paclitaxel. *:p < 0.05, **:p < 0.01